NTRA:NSD-Natera Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 127.1

Change

-0.11 (-0.09)%

Market Cap

USD 15.65B

Volume

0.87M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-0.97 (-0.19%)

USD 41.20B
ICLR ICON PLC

+9.91 (+3.39%)

USD 24.84B
ILMN Illumina Inc

+0.76 (+0.58%)

USD 20.58B
EXAS EXACT Sciences Corporation

+1.22 (+1.79%)

USD 11.40B
MEDP Medpace Holdings Inc

+6.64 (+1.87%)

USD 10.90B
RDNT RadNet Inc

+0.30 (+0.45%)

USD 5.01B
SHC Sotera Health Co

+0.08 (+0.48%)

USD 4.76B
NEOG Neogen Corporation

+0.37 (+2.19%)

USD 3.50B
GH Guardant Health Inc

-0.01 (-0.04%)

USD 3.30B
TWST Twist Bioscience Corp

-0.65 (-1.36%)

USD 2.75B

ETFs Containing NTRA

EKG First Trust Nasdaq Lux Di.. 5.29 % 0.00 %

-0.01 (-1.03%)

USD 2.48M
CURG:LSE VanEck Genomics and Healt.. 5.13 % 0.00 %

-0.16 (-1.03%)

USD 7.21M
GNOG:LSE Global X Genomics & Biote.. 4.95 % 0.00 %

-0.09 (-1.03%)

USD 5.90M
GNOM Global X Genomics & Biote.. 4.95 % 0.00 %

-0.09 (-1.03%)

USD 0.08B
CURE:XETRA VanEck Genomics and Healt.. 4.55 % 0.00 %

-0.12 (-1.03%)

N/A
GN0M:XETRA Global X Genomics & Biote.. 4.52 % 0.00 %

-0.08 (-1.03%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.52 % 0.00 %

-0.04 (-1.03%)

USD 6.07M
FRTY Alger Mid Cap 40 ETF 4.34 % 0.00 %

-0.06 (-1.03%)

USD 0.05B
ARCG:LSE ARK Genomic Revolution UC.. 3.86 % 0.00 %

-10.00 (-1.03%)

USD 2.92M
PTH Invesco DWA Healthcare Mo.. 3.31 % 0.60 %

+0.25 (+-1.03%)

USD 0.15B
ATFV Alger 35 ETF 3.05 % 0.00 %

-0.03 (-1.03%)

USD 0.02B
WBIO:LSE WisdomTree BioRevolution .. 2.87 % 0.00 %

-21.00 (-1.03%)

USD 3.72M
WDNA 2.66 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.61 % 0.00 %

-0.21 (-1.03%)

USD 2.77M
FXH First Trust Health Care A.. 2.40 % 0.63 %

-0.02 (-1.03%)

USD 1.29B
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

-0.23 (-1.03%)

N/A
FHH-F:CA First Trust AlphaDEX U.S... 2.22 % 0.00 %

N/A

CAD 0.01B
DOCG:LSE L&G Healthcare Breakthrou.. 1.92 % 0.00 %

-12.75 (-1.03%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.91 % 0.00 %

-0.15 (-1.03%)

USD 0.07B
XMLH:XETRA L&G Healthcare Breakthrou.. 1.78 % 0.00 %

-0.13 (-1.03%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.78 % 0.00 %

+0.06 (+-1.03%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.78 % 0.00 %

-0.05 (-1.03%)

USD 0.07B
FNY First Trust Mid Cap Growt.. 0.82 % 0.70 %

-0.03 (-1.03%)

USD 0.35B
SCHA Schwab U.S. Small-Cap ETF 0.40 % 0.05 %

+0.02 (+-1.03%)

USD 17.65B
IS0R:XETRA iShares High Yield Corpor.. 0.34 % 0.00 %

-0.06 (-1.03%)

USD 2.71B
IUSN:XETRA iShares MSCI World Small .. 0.19 % 0.00 %

-0.05 (-1.03%)

USD 3.82B
BTEC 0.00 % 0.42 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

+0.14 (+-1.03%)

CAD 0.27B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.05 (-1.03%)

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.06 (-1.03%)

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

-0.15 (-1.03%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 102.91% 94% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 102.91% 94% A 95% A
Trailing 12 Months  
Capital Gain 158.54% 94% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 158.54% 94% A 96% N/A
Trailing 5 Years  
Capital Gain 276.93% 94% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 276.93% 94% A 94% A
Average Annual (5 Year Horizon)  
Capital Gain 47.10% 82% B 89% A-
Dividend Return 47.10% 82% B 89% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 88.69% 36% F 20% F
Risk Adjusted Return 53.11% 92% A 80% B-
Market Capitalization 15.65B 93% A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector